- NMRD has developed a proprietary technology that replaces traditional invasive methods of diagnosis and healthcare observation procedures
- Report notes that study participants are interested in using electronic methods to communicate more with their doctors between visits
- Better communication between patients and their healthcare providers impacts adherence to prescribed treatment
According to a report published in Dove Medical Press, communication between patients and their physicians has a notable impact on adherence to prescribed treatment and improved health care (https://nnw.fm/mbGeJ). As a company focused on providing digital and glucose monitoring solutions for patients dealing with diabetes, Nemaura Medical (NASDAQ: NMRD) pays special attention to essential information and research that impacts the successful implementation of its solutions.
“Many patients are not satisfied with how their doctors communicate with them,” the report states. “Patients want to be more involved in planning their care and making decisions about their treatment. It is often difficult for patients to understand all the instructions from their doctors, especially when they receive too much information at one time. This is especially true for patients with chronic diseases, such as diabetes, where treatment is complicated and lifelong. Using electronic methods, such as smartphones, email, or text message, may help improve communication between patients and doctors.”
These conclusions originate from a study titled “Mechanisms for improving diabetes patient–provider communication through optimal use of e-clinical technologies.” The study included a survey of 105 participants with type 2 diabetes, which indicated that most participants were interested in using electronic methods to communicate more with their doctors between visits.
“Participants showed interest in using email to communicate with their doctor, and using a smartphone for medication reminders and scheduling doctor visits,” the report noted. “Patients need support and encouragement from their doctors, especially when dealing with lifelong complicated treatments, such as for type 2 diabetes. Our study shows that patients with type 2 diabetes are willing and interested in using electronic methods to increase communication with their doctors to manage their disease. This suggests that health care providers should consider using electronic methods to increase communication with the goal to improve health care.”
These findings are particularly interesting to Nemaura, which has developed a proprietary technology that replaces traditional invasive methods of glucose monitoring that can be useful in disease management and diagnosis. NMRD’s BEAT(R) solution allows for continuous remote monitoring of chronic diseases and health conditions. Based on a world-class program initially developed at the Joslin Diabetes Center, BEAT is designed to help people with diabetes manage their condition and even potentially reverse type 2 diabetes using a combination of data from a wearable sensor and digital intervention and coaching.
Nemaura’s BEAT is combined with the company’s proprietary sugarBEAT(R) sensor platform, which is the world’s first non-invasive daily-wear continuous glucose monitoring designed for use by people with both type 1 and type 2 diabetes as well as pre-diabetes, to trend glucose profiles. “Importantly, as a daily disposable adhesive skin-patch that sits on the surface of the skin, SugarBEAT is painless and versatile in terms of wear time,” said Nemaura CEO Dr. Faz Chowdhury (https://nnw.fm/UkIvg). “Due to the non-invasive nature of the sensor patch and connection to a rechargeable transmitter, SugarBEAT will allow users the freedom to decide when, and for how long to wear the patch.”
This commitment to offering solutions designed to support patients in their treatment plans makes Nemaura distinctive — and that makes reports like the one published by Dove exciting. The company recently tweeted about the report (https://nnw.fm/7dBUx), noting “the power of patient–provider communication. Optimal use of e-clinical technologies paves the way.”
For more information, visit the company’s website at www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://nnw.fm/NMRD
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
